SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-019637
Filing Date
2019-05-16
Accepted
2019-05-16 16:26:26
Documents
71
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ngm-10q_20190331.htm 10-Q 2415605
2 EX-31.1 ngm-ex311_359.htm EX-31.1 15329
3 EX-32.1 ngm-ex321_360.htm EX-32.1 5970
  Complete submission text file 0001564590-19-019637.txt   9741104

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT ngm-20190331.xml EX-101.INS 2430852
5 XBRL TAXONOMY EXTENSION SCHEMA ngm-20190331.xsd EX-101.SCH 63079
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20190331_cal.xml EX-101.CAL 40426
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20190331_def.xml EX-101.DEF 247252
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20190331_lab.xml EX-101.LAB 496161
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20190331_pre.xml EX-101.PRE 405190
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38853 | Film No.: 19832590
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences